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Safety and efficacy of exposure to
bedaquiline−delamanid in multidrug-
resistant tuberculosis: a case series from
France and Latvia
To the Editor:
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) represent a therapeutic
challenge [1]. Two anti-TB agents, bedaquiline and delamanid, have been recently approved for the
treatment of MDR/XDR-TB. Bedaquiline has a terminal half-life of 5.5 months, in contrast with the short
half-life of delamanid (38 h). Both drugs increase the QTcF (Fridericia-corrected QT) interval, although
no clinically significant cardiac events have been reported in patients treated with one of these drugs [2, 3].
The clinical trials that led to approval of bedaquiline and delamanid tested these drugs by adding one of
them, for a duration of 24 weeks and 6–8 months, respectively, to optimised background [2, 3]. To date,
only six cases treated with the bedaquiline−delamanid combination have been reported, mostly presenting
interim results [4–6]. The World Health Organization (WHO) recommends to use these drugs for a
standardised duration of 24 weeks, the concomitant use of bedaquiline and delamanid being restricted to
patients with “no other therapeutic options”. Otherwise, it is recommended to start the two drugs
sequentially after a washout period of 6 months, when switching from bedaquiline to delamanid, and
5 days, when switching from delamanid to bedaquiline [7]. We report the results of exposure to
concomitant and sequential treatment with bedaquiline and delamanid, including treatment courses
beyond 24 weeks, as part of multidrug MDR/XDR-TB regimens.
A multicentre case series was established including patients who started treatment for culture-proven
MDR-TB from January 1, 2013 to August 31, 2015, and were exposed to the bedaquiline−delamanid
combination for ⩾30 days. Participating centres were three hospitals in the Paris region, France (Bligny,
Pitié-Salpêtrière and Bichat), and the Riga East University Hospital in Riga, Latvia. Exposure to
bedaquiline and delamanid was defined as the sum of: 1) days of concomitant treatment; and 2) days of
exposure to one drug after stopping it, as defined by washout period, while taking the other one
(sequential treatment). Standard definitions of MDR/XDR-TB and WHO treatment outcomes were
applied. Time to sputum culture conversion was measured from treatment start to the first of two
consecutive negative sputum culture results. Treatment regimens were tailored for each patient in
agreement with WHO guidance: concomitant or sequential treatment with bedaquiline and delamanid was
used to provide regimens with at least four effective drugs to patients with resistance or intolerance to
second-line drugs. Bedaquiline and delamanid treatment courses were prolonged beyond 24 weeks
according to criteria presented elsewhere [8]. Individualised treatment oversight was provided by the
French and Latvian TB Consilia. Adequate treatment monitoring, including periodic ECGs as
recommended, and pharmacovigilance were implemented. Treatment was usually started under inpatient,
and then continued under outpatient care. Seriousness of adverse events was defined according to the US
National Institutes of Health CTCAE version 4.0 [9]. Data were collected retrospectively from medical
records. Ethics approval for the study was granted by the institutional review board of the coordinating
centre in France (Bligny Hospital), and of the University of Latvia. Patients were informed about potential
benefits and risks of treatment, including bedaquiline−delamanid exposure, and provided verbal consent
to undergo the treatment.
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TABLE 1 Characteristics of the 10 multidrug-resistant pulmonary tuberculosis patients exposed to bedaquiline and delamanid treatment
Patient Age
years
TB form Resistance profile






































1 55 S+ C+
Cav+ Bil+
Z, E, Ofx, Eto, PAS Concomitant 63/428 448 48 Cs, Lzd Mfx(400) 438 (5) Lzd (optic
neuritis)
No 23 Cure
2 29 S− C+
Cav+ Bil−
Z, E, S, Ofx, Mfx,
Km, Eto, PAS, Cs,
Bdq
Concomitant 113/636 749 180 PAS, Am, Lzd Mfx(800), Cfz 459 (21) PAS (vomiting),
Am (hearing loss)
No 55 Cure
3§ 20 S+ C+
Cav+ Bil+
Z, S, Ofx, Mfx, Am,
Km, Cm, Eto, Cs





4 32 S+ C+
Cav+ Bil+
Z, E, S, Ofx, Mfx,
Eto, PAS, Cs
Concomitant 732/142 732 147 Am, Lzd, Ipm,
Amx/Clv





5 46 S+ C+
Cav+ Bil−
Z, E, S, Ofx, Mfx,
Km, Eto, Cs,




6 30 S+ C+
Cav+ Bil+
Z, E, S, Ofx, Mfx,
Eto, Lzd
Concomitant 735/700 735 700 Am, Cs, PAS,
Ipm, Amx/Clv
Cfz >500 (5) Cfz (QT
prolongation)
No 87 Cure
7 33 S+ C−
Cav+ Bil+
Z, E, S, Ofx, Mfx,




56/286 286 160 PAS, Lzd, Ipm,
Amx/Clv
Cfz 472 (1) No Na LTFU
8 36 S+ C−
Cav+ Bil+
Z, E, S, Ofx, Mfx,









9 40 S+ C+
Cav+ Bil+
Z, E, S, Ofx, Mfx,




67/698 744 180 Cm, Cs, PAS,
Lzd
Mfx(800), Cfz 447 (11) Lzd (peripheral
neuropathy)
No 39 Cure
10 25 S+ C+
Cav+ Bil+




426/286 731 161 Am, PAS, Cs,
Lzd





#: for sequential treatment, time in days from bedaquiline discontinuation to delamanid start is shown in brackets; ¶: exposure was calculated as the sum of concomitant treatment and,
for sequential treatment of bedaquiline and delamanid, time until the end of the washout period (180 days for bedaquiline); +: event occurred before the exposure to the bedaquiline/
delamanid combination; §: preliminary data of patient 3 have been previously described elsewhere [4]. TB: tuberculosis; QTcF: QT interval corrected according to the Fridericia formula;
S+: sputum smear positive at treatment start; S−: sputum smear negative at treatment start; C+: sputum culture positive at treatment start; C−: sputum culture negative at treatment
start; Cav+: presence of at least one lung cavity at treatment start; Bil+: bilateral lung involvement at treatment start; Bil−: unilateral lung involvement at treatment start; LTFU: lost to
follow-up; R: rifampicin; H: isoniazid; Bdq: bedaquiline; Dlm: delamanid; Z: pyrazinamide; E: ethambutol; S: streptomycin; Ofx: ofloxacin; Mfx(400): moxifloxacin (400 mg·day−1); Mfx(800):
moxifloxacin (800 mg·day−1); Am: amikacin; Km: kanamycin; Cm: capreomycin; Eto: ethionamide; Cs: cycloserine; PAS: para-aminosalicylic acid; Lzd: linezolid; Cfz: clofazimine; Ipm:

















Overall, 10 patients were included in the study (table 1). All patients were male; nine were previously treated
for TB. The median age was 32 years (interquartile range (IQR) 28–41 years). All patients had a phenotypic
drug susceptibility test showing resistance to rifampicin and isoniazid at baseline, plus additional resistance
to a median of eight drugs (IQR 6–9). Six fulfilled the definition of XDR-TB, and four had
fluoroquinolone-resistant MDR-TB. Resistance to bedaquiline was detected in four cases, as previously
reported [10]. In three cases (patients 2, 7 and 9), bedaquiline resistance was found in the baseline
specimen and led to replacement of the drug with delamanid. Patient 8 developed bedaquiline resistance on
treatment, as reported elsewhere [8], and started a new delamanid-containing regimen. All patients had
cavitary pulmonary TB, eight with bilateral lung involvement. Nine patients had smear-positive sputum at
baseline. None had extrapulmonary TB. Four had PCR-positive HCV infection and one had chronic HBV
hepatitis. No patient had HIV infection, or diabetes. Overall, six patients received concomitant bedaquiline−
delamanid treatment, and four were treated initially with bedaquiline and then switched to delamanid
without (or with incomplete) washout. Six patients received prolonged (>24 weeks) treatment with
bedaquiline, and nine with delamanid: respective median treatment durations were 391 (IQR 66–733) and
532 (IQR 286–701) days. Median exposure to the combination of bedaquiline and delamanid was 171 (IQR
138–327) days, with two patients receiving concomitantly the two drugs for the full treatment course. The
most commonly co-administered drugs were clofazimine (70%) and linezolid (60%). Notably, four patients
received one QT-prolonging drug, namely clofazimine or moxifloxacin, and four received both. Three
patients underwent lung surgery (lobectomy) after a median of 125 (range 114–328) days from treatment
start; all of them had converted their sputum cultures prior to the surgery date. All patients experienced at
least one adverse event, and four patients had a serious adverse event (table 1). No >60 ms QTcF increase
occurred during treatment. QTcF >500 ms values were reported in two patients. One was receiving a
regimen including bedaquiline, delamanid and clofazimine; his QTcF interval reverted to normal after the
discontinuation of clofazimine. The other was on treatment with a regimen which included bedaquiline and
moxifloxacin at 800 mg·day−1; after the discontinuation of moxifloxacin, the QTcF interval decreased below
500 ms, allowing the introduction of delamanid. Overall, no arrhythmia or other cardiac event was
recorded. Delamanid was discontinued in a patient who developed adrenal insufficiency, and bedaquiline
was discontinued in a patient experiencing oligoarthritis and osteonecrosis. Out of eight patients with a
positive sputum culture at treatment initiation, all achieved sputum culture conversion after 3 months of
treatment (median time to culture conversion 77 (IQR 43–88) days). Overall, nine patients were cured and
one was lost to follow-up after 8 months of treatment; at the last visit, he had culture-negative sputum.
We report the use of bedaquiline and delamanid in 10 MDR-TB patients. Prolonged periods of exposure
to these two drugs, including use beyond 24 weeks, appeared to be rather well tolerated. QTcF >500 ms
was recorded in two cases of co-administration of multiple QT-prolonging drugs; however, the overall
cardiac safety was good in these patients, confirming recent studies [11, 12]. Regular ECG monitoring
allowed timely identification and management QT prolongation above 500 ms, which may have
contributed in preventing cardiac events. The adverse events that led to the discontinuation of bedaquiline
(patient 10) and delamanid (patient 4) had not been described before in association with these drugs, and
therefore causality assessment was uncertain. Successful treatment outcomes were observed for nine of the
10 patients, despite advanced resistance patterns, including fluoroquinolone resistance in all cases. Overall,
these results suggest that, in cases where scarce therapeutic options are available, these drugs could be used
concomitantly, rather than sequentially with washout, to prevent the selection of drug resistance [13]. This
study has some limitations, including the small sample size, retrospective data collection, and
unavailability of systematic monitoring of blood levels of bedaquiline and delamanid.
In conclusion, our results show good tolerance of exposure to the combination of bedaquiline and
delamanid for the treatment of MDR/XDR-TB. Ongoing clinical trials (DELIBERATE (NCT02583048),
and endTB (NCT02754765)) will provide high-quality evidence on the combination. Meanwhile, these
findings should encourage considering this treatment option for patients with limited therapeutic
alternatives [14, 15].
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